BillionToOne SVP John Roderick Ten Bosch offloaded 1,416 shares via a Rule 10b5-1 plan, maintaining a significant $2.4 million stake in the molecular diagnostics firm.
Insider sold 1,416 shares under a Rule 10b5-1 plan, representing routine portfolio management with retained stake.
BillionToOne SVP of Laboratory Operations John Roderick Ten Bosch sold 1,416 shares of Class A Common Stock on September 9, 2026. The transaction, valued at approximately $138,117, was executed under a pre-established Rule 10b5-1 trading plan. Despite the sale, Ten Bosch retains a direct stake of 25,051 shares, valued at roughly $2.4 million, signaling routine portfolio management rather than a shift in corporate outlook.
No, the transaction was executed under a pre-established Rule 10b5-1 plan, which is typically used by executives to manage personal finances without regard to non-public information.
The company reported $397.4 million in TTM revenue and $31.9 million in net income, with analysts projecting annualized revenue growth of approximately 37% over the next two years.